Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNancy TorresSBSushma BharadwajHEHany Elmariah

Discussion

Loading...

Member takes

Overview

Retrospective review shows allogeneic HCT improves outcomes in TP53-mutated AML/MDS, suggesting conditioning intensity impacts relapse rates.

Key Points

  • This research aims to assess the outcomes of allogeneic HCT in patients with TP53-mutated AML/MDS lacking complex or monosomal karyotype.
  • Retrospective review of 67 AML/MDS patients who underwent HCT between 2015-2024
  • Categorization into cohorts based on TP53 mutation status and karyotype
  • Analysis of survival outcomes using Kaplan-Meier methods
  • Measurement of TP53 variant allele frequencies and measurable residual disease detection
  • Overall median OS was 19.2 months with 55.2% 1-year OS within the cohort
  • TP53-only patients had a median OS of 25.7 months, while CK/MK-only had 10.7 months
  • CIR1 was significantly lower in TP53-only patients at 18.2% compared to CK/MK-only at 65.0%
  • Patients receiving reduced intensity conditioning had longer median OS compared to myeloablative and nonmyeloablative conditioning

Cite This Study

Torres et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d461https://doi.org/10.1182/blood-2025-2525
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  2. 2Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025
  3. 3Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  4. 4Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  5. 5Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations